ERBB2 and neoplasm: In the above-mentioned TRIUMH trial, investigators evaluated the application of an artificial intelligence (AI)-powered HER2 quantification continuous score (QCS) in 30 tumor samples with proven HER2 amplification by HER2 FISH or ctDNA analysis, and the results were recently presented at ASCO 2023 [124].